Background: Volume doubling time (VDT) has been proven to be a powerful predictor of lung cancer progression. In non-small cell lung cancer patients receiving sublobar resection, the discussion of correlation between VDT and surgery was absent. We proposed to investigate the surgical outcomes according to VDT. Methods: We retrospectively studied 96 cases post sublobar resection from 2012 to 2018, collecting two chest CT scans preoperatively of each case and calculating the VDT. The receiver operating characteristic curve was constructed to identify the optimal cut-off point of VDTs as 133 days. We divided patients into two groups: VDT < 133 days and VDT ≥ 133 days. Univariable and multivariable analyses were performed for comparative purposes. Results: Univariable and multivariable analyses revealed that the consolidation and tumor diameter ratio was the factor of overall survival (OS), and VDT was the only factor of disease-free survival (DFS). The five year OS rates of patients with VDTs ≥ 133 days and VDTs < 133 days, respectively, were 89.9% and 71.9%, and the five year DFS rates were 95.9% and 61.5%. Conclusion: As VDT serves as a powerful prognostic predictor and provides an essential role in planning surgical procedures, the evaluation of VDT preoperatively is highly suggested.
背景：体积倍增时间已被证实是预测肺癌进展的重要指标。在非小细胞肺癌患者接受亚肺叶切除术的背景下，关于体积倍增时间与手术关联性的讨论尚属空白。本研究旨在基于体积倍增时间探讨手术预后。方法：我们回顾性分析了2012年至2018年间96例接受亚肺叶切除术的病例，收集每位患者术前两次胸部CT扫描数据并计算体积倍增时间。通过构建受试者工作特征曲线，确定133天为体积倍增时间的最佳截断值。将患者分为体积倍增时间<133天组和≥133天组，并进行了单变量与多变量分析比较。结果：单变量与多变量分析显示，实变与肿瘤直径比是总生存期的独立影响因素，而体积倍增时间是唯一与无病生存期相关的因素。体积倍增时间≥133天组患者的五年总生存率为89.9%，<133天组为71.9%；五年无病生存率分别为95.9%和61.5%。结论：体积倍增时间作为重要的预后预测指标，对手术方案制定具有关键指导意义，建议术前积极进行体积倍增时间评估。
肿瘤(癌症)患者之家